Literature DB >> 12695347

Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1.

Yuichiro Watanabe1, Miki Nakajima, Noriko Ohashi, Toshiyuki Kume, Tsuyoshi Yokoi.   

Abstract

A metabolite formed by incubation of human liver microsomes, etoposide, and UDP-glucuronic acid was identified as etoposide glucuronide by liquid chromatography-tandem mass spectrometry analysis. According to the derivatization with trimethylsilylimidazole (Tri-Sil-Z), it was confirmed that the glucuronic acid is linked to an alcoholic hydroxyl group of etoposide and not to a phenolic group. Among nine recombinant human UGT isoforms (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9. UGT1A10, UGT2B7, and UGT2B15), only UGT1A1 exhibited the catalytic activity of etoposide glucuronidation. The enzyme kinetics in pooled human liver microsomes and recombinant UGT1A1 microsomes showed a typical Michaelis-Menten plot. The kinetic parameters of etoposide glucuronidation were K(m) = 439.6 +/- 70.7 microM and V(max) = 255.6 +/- 19.2 pmol/min/mg of protein in human liver microsomes and K(m) = 503.2 +/- 110.2 microM and V(max) = was 266.5 +/- 28.6 pmol/min/mg of protein in recombinant UGT1A1. The etoposide glucuronidation in pooled human liver microsomes was inhibited by bilirubin (IC(50) = 31.7 microM) and estradiol (IC(50) = 34 microM) as typical substrates for UGT1A1. The inhibitory effects of 4-nitrophenol (IC(50) = 121.0 microM) as a typical substrate for UGT1A6 and UGT1A9, imipramine (IC(50) = 393.8 microM) as a typical substrate for UGT1A3 and UGT1A4, and morphine (IC(50) = 109.3 microM) as a typical substrate for UGT2B7 were relatively weak. The interindividual difference in etoposide glucuronidation in 13 human liver microsomes was 78.5-fold (1.4-109.9 pmol/min/mg of protein). The etoposide glucuronidation in 10 to 13 human liver microsomes was significantly correlated with beta-estradiol-3-glucuronidation (r = 0.841, p < 0.01), bilirubin glucuronidation (r = 0.935, p < 0.01), and the immunoquantified UGT1A1 protein content (r = 0.800, p < 0.01). These results demonstrate that etoposide glucuronidation in human liver microsomes is specifically catalyzed by UGT1A1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695347     DOI: 10.1124/dmd.31.5.589

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

Authors:  Jose Claudio C Rocha; Cheng Cheng; Wei Liu; Shinji Kishi; Soma Das; Edwin H Cook; John T Sandlund; Jeffrey Rubnitz; Raul Ribeiro; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

3.  Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Authors:  Sabrina Jones; Azure L Yarbrough; Amal Shoeib; John M Bush; William E Fantegrossi; Paul L Prather; Anna Radominska-Pandya; Ryoichi Fujiwara
Journal:  Xenobiotica       Date:  2019-03-20       Impact factor: 1.908

4.  Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.

Authors:  Yutaka Negoro; Ryoichi Yano; Mari Yoshimura; Yoko Suehiro; Shinji Yamashita; Takaaki Kodawara; Kyohei Watanabe; Hitoshi Tsukamoto; Toshiaki Nakamura; Maiko Kadowaki; Miwa Morikawa; Yukihiro Umeda; Masaki Anzai; Tamotsu Ishizuka; Nobuyuki Goto
Journal:  Int J Clin Oncol       Date:  2018-10-17       Impact factor: 3.402

6.  Etoposide pathway.

Authors:  Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V Relling; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

Review 7.  UGT genotyping in belinostat dosing.

Authors:  Andrew K L Goey; William D Figg
Journal:  Pharmacol Res       Date:  2016-01-07       Impact factor: 7.658

Review 8.  Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases.

Authors:  Ryoichi Fujiwara; Tsuyoshi Yokoi; Miki Nakajima
Journal:  Front Pharmacol       Date:  2016-10-24       Impact factor: 5.810

9.  Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.

Authors:  Renata Rezonja; Lea Knez; Tanja Cufer; Ales Mrhar
Journal:  Radiol Oncol       Date:  2013-02-01       Impact factor: 2.991

10.  Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.

Authors:  Guillermo Gervasini; Jose M Vagace
Journal:  Front Genet       Date:  2012-11-22       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.